ABIONYX Pharma SA ABNX

WOIPPY, France, October 01, 2026--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical research, s raising its revenue guidance for the financial year ending 31 December 2026. Based on the commercial, operational and accounting information available as of the date of this press release, the Company now expects revenue to be between €13.5

TOULOUSE, France & FULLERTON, Calif., September 23, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, today announced its financial results for the first half of 2026.

TOULOUSE, France & FULLERTON, Calif., September 10, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, announces the establishment of a strategic partnership with TEXCELL, a division of ABL Diagnostics, for the viral safety and clearance testing of its biopharmaceutical development.

WOIPPY, France, September 10, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD - ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software and clinical research services, today announced the conclusion of a strategic partnership with ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies in sepsis and intensive care, based on an exclusive apoA-I-based technology plat

TOULOUSE, France & FULLERTON, Calif., August 27, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provides an update on its activity and cash position as of June 30, 2026.

TOULOUSE, France, August 04, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):

TOULOUSE, France, July 06, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):

TOULOUSE, France, July 06, 2026--Regulatory News: Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account as of June 30, 2026:

TOULOUSE, France & FULLERTON, Calif., June 30, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I-based technology platform, today provided an update on the Combined General Meeting held at the company’s headquarters and the new phase of development beginning on June 30, 2026.

TOULOUSE, France & FULLERTON, Calif., June 18, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) ("Abionyx" or the "Company"), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its exclusive apoA-I technology platform, today announces the success of its capital increase with preferential subscription rights (the "Rights Issue"), launched on May 27, 2026, which has been subscribed at 100% after partial

TOULOUSE, France & FULLERTON, Calif., June 09, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on a proprietary apoA-I technology platform, hereby notifies the public that the Company’s Combined Annual General Meeting will be held on Tuesday, June 30, 2026, at 4:00 p.m., at the Company’s registered office, 33-43 Av. Georges Pompidou, 31130 Balma, France.

The European markets have shown a mixed performance, with the pan-European STOXX Europe 600 Index ending the week slightly up amid ongoing geopolitical tensions and economic uncertainties. Amid these broader market conditions, investors often look for opportunities beyond established names, and penny stocks can offer intriguing possibilities. While the term "penny stock" might seem outdated, it still signifies smaller or newer companies that can present unique opportunities. We've identified...